发明名称 PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE
摘要 <P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, in which the pharmaceutical composition has efficacy the same as or higher than those of conventional formulations and has no limitations on food intake. <P>SOLUTION: The pharmaceutical composition for modified release includes (1) (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical formulation and which has solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or viscosity of 12 mPa s or more at a 5% aqueous solution at 25&deg;C. <P>COPYRIGHT: (C)2011,JPO&INPIT
申请公布号 JP2011079859(A) 申请公布日期 2011.04.21
申请号 JP20100276634 申请日期 2010.12.13
申请人 ASTELLAS PHARMA INC 发明人 TAKAISHI YUUKI;TAKAHASHI YUTAKA;NISHIZATO TAKASHI;MURAYAMA DAISUKE;MURAYAMA EMIKO;NAKAMURA SOICHIRO;SAKO KAZUHIRO
分类号 A61K31/426;A61K47/02;A61K47/10;A61K47/12;A61K47/14;A61K47/18;A61K47/22;A61K47/26;A61K47/32;A61K47/34;A61K47/36;A61K47/38;A61P3/04;A61P3/06;A61P3/10;A61P13/10 主分类号 A61K31/426
代理机构 代理人
主权项
地址